Following the protocol from Amabile et al, 3 who propose systematic triton lysis as a control to prove the vesicular nature of the MP population, we agree that the use of triton lysis can be a validating step for many MP-IC applications by FCM, as we also saw MP population dissolve from the MP gate. However, using the triton lysis we observed an impact on the IC population (data not shown). Under our conditions, as both populations are distinguishable by light scatter alone, the use of triton lysis in this instance added an unnecessary and complicating step.
7. Robert S, Poncelet P, Lacroix R, Raoult D, Dignat-George F. More on: calibration for the measurement of microparticles: value of calibrated polystyrene beads for flow cytometry-based sizing of biological microparticles. J Thromb Haemost. 2011;9(8):1676-1678.
To the editor:
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia
The JAK1/JAK2 inhibitor ruxolitinib was recently approved for intermediate and high-risk myelofibrosis. However, for malignancies with JAK2 rearrangements, known for their rapid evolution and dismal prognosis, the potential of JAK inhibitor therapy is not established. 1 We investigated the efficacy of ruxolitinib against JAK2 fusions in vitro and in a patient with t(8;9)(p22;p24)/PCM1-JAK2 chronic eosinophilic leukemia (CEL).
A 72-year-old male presented with leukocytosis of 49 ϫ 10 9 /L, absolute eosinophil count of 23 ϫ 10 9 /L and circulating myeloid progenitors. Specific symptoms were absent and clinical examination was unremarkable. Bone marrow aspirate and biopsy were hypercellular with prominent myelopoiesis, pronounced eosinophilia, and hypergranulated granulocyte precursors ( Figure 1A) . Cytogenetics showed 46,XY,t(8;9)(p22;p24) in 33 of 35 metaphases, and FISH confirmed the breakpoints in 8p22 (PCM1) and 9p24 (JAK2; Figure 1B ). RT-PCR and Sanger sequencing showed an in-frame fusion between PCM1 exon 36 and JAK2 exon 9, as in the first case reported. 2 This PCM1-JAK2 fusion was cloned and additional ETV6-JAK2 and SEC31A-JAK2 constructs were generated. In Ba/F3 cells, PCM1-JAK2, ETV6-JAK2, and SEC31A-JAK2 induced growthfactor independent growth, [3] [4] [5] which was suppressed by ruxolitinib with IC 50 values of 57, 46, and 92nM, respectively ( Figure 1C) . Western blotting showed dose-dependent inhibition of phosphorylation of JAK2, indicating a direct and specific action of ruxolitinib, and of downstream STAT5 ( Figure 1C ). For comparison, the growth of JAK2-V617F-expressing Ba/F3 was inhibited with 106nM as IC 50 , in line with published data. 5, 6 Similar data were obtained for JAK inhibitor I, a JAK1/JAK2/JAK3/TYK2 inhibitor (not shown).
Given this, and lacking effective medical treatment options, ruxolitinib was initiated after approval from the ethical committee and patient informed consent. Since diagnosis, the leukocyte count had been controlled with hydroxyurea 250-2000 mg/d, but the peripheral eosinophilia remained elevated. Multiple transfusions and dose adjustments were required for anemia, with corresponding fluctuations in leucocytes and eosinophils. After 15 months, ruxolitinib was started at 10 mg twice daily. At this point, 25 of 30 marrow metaphases were t(8;9)-positive ( Figure 1D -E). Ruxolitinib was cautiously increased to 15-20 mg bid and hydroxyurea could be discontinued 6 months later. By then, the eosinophil count had normalized, and the thrombocytopenia partially recovered. Moreover, the number of t(8;9) metaphases had decreased to 10 of 30. Continuing ruxolitinib as single agent, the eosinophil count remained normal. Marrow examinations after 11 and 15 months ruxolitinib therapy were hypocellular without evidence of CEL. After 15 months, a complete cytogenetic response (0 abnormal of 26 analyzed metaphases) was reached; and the number of interphase nuclei with a JAK2/ 9p24 breakpoint in FISH had equally decreased to less than 5%. FISH on a cytogenetic marrow specimen at diagnosis. Dual color JAK2 break-apart FISH was performed using the following probes: RP11 307I14-RP11 125K10-RP11 509D8 (Spectrum Green) and RP11 140C18-RP11 635N21 (Spectrum Orange), as described. 5 The t(8;9) leads to translocation of the green signal to der(8), while the red probes and a tiny little green signal are retained on the der(9) (solid arrows). The same break-apart pattern is observed in interphase cells (dotted arrows). 1530 CORRESPONDENCE BLOOD, 16 AUGUST 2012 ⅐ VOLUME 120, NUMBER 7 For personal use only. on July 31, 2017. by guest www.bloodjournal.org To the editor:
Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension
Pulmonary hypertension (PH) is a frequent complication and one of the leading causes of mortality in patients with hemolytic disorders. [1] [2] [3] [4] The pathophysiology of PH in hemoglobinopathies is multifactorial including chronic tissue hypoxia, high cardiac output, hemolysis, hypercoagulopathy, splenectomy, iron overload and chronic lung injury. 5 Chronic hemolytic anaemias have been included in group 1-pulmonary arterial hypertension (PAH) in the updated clinical classification of PH (Dana Point, 2008). 6 Although the efficacy of the PAH-specific therapy has been established in group 1, its role in patients with hemoglobinopathies remains unclear. Most data regarding the use of the PAH-specific therapy in this patient population come from studies in patients with sickle cell disease, [7] [8] [9] while the relevant data in thalassemic patients are very limited. 10, 11 We report a case of a patient with thalassemia intermedia (TI) and PAH defined by right heart catheterization (RHC), successfully treated with the dual endothelin-1 receptor antagonist bosentan. To the best of our knowledge there is no published study, based on data from RHC, evaluating the effects of PAH-specific therapy in these patients.
A 46-year-old female with TI, diagnosed at 10 years of age, presented to the Attikon University Hospital PH clinic with an 8-month history of progressive shortness of breath on exertion.
In the past, she had mild symptoms and was independent from transfusions until 40 years of age, when she underwent splenectomy and started receiving occasional blood transfusions. At that time prophylactic anticoagulation therapy was initiated. Three years later, at 43 years of age, the patient started a program of regular blood transfusions (2 units of packed red blood cells per month) and iron chelation therapy that continued without change over the next 3 years maintaining stable hemoglobin levels (9-10 g/dL). She never received hydroxyurea therapy. No thrombotic event was ever diagnosed.
On presentation, she was in functional class III, her 6-minutewalk-test was 480 m and plasma NT-proBNP level was at 235 pg/ mL. Transthoracic echocardiography revealed a tricuspid regurgitant jet velocity of 4.6 m/s, and left ventricular ejection fraction of The starting dose of bosentan was 62.5 mg twice daily and increased after 4 weeks to 125 mg twice daily.
PRBC indicates packed red blood cells; NT-pro BNP, N-terminal fragment of the brain-natriuretic peptide; NYHA, New York Heart Association; 6 MWT, 6 minute walk test; RAP, right atrium pressure; PAP(S/D/M), pulmonary artery pressure (systolic, diastolic, mean); PCWP, pulmonary capillary wedge pressure; CO, cardiac output; CI, cardiac index; PVR, pulmonary vascular resistance; SvO2, mixed venous oxygen saturation; and N/A, not available.
